Please wait while the formulary information is being retrieved.
DORAL (QUAZEPAM)
- Insomnia
15 mg tablet
- one-half tablet (7.5 mg) by oral route once daily at bedtime as needed
15 mg tablet
- one-half tablet (7.5 mg) by oral route once daily at bedtime as needed
Insomnia
- 1 tablet (15 mg) by oral route once daily at bedtime as needed
- 1 tablet (15 mg) by oral route once daily before bedtime
- one-half tablet (7.5 mg) by oral route once daily at bedtime
- one-half tablet (7.5 mg) by oral route once daily at bedtime as needed
- Xyrem
- sodium oxybate
Contraindicated
- Versacloz
- Symbyax
- Sarafem
- Prozac Weekly
- Prozac
- olanzapine-fluoxetine
- nefazodone
- Lydia Pinkham Herbal
- Luvox Cr
- fluvoxamine
- fluoxetine
- Fazaclo
- ethyl alcohol-herbal drugs
- ethanol (ethyl alcohol)
- Dehydrated Alcohol
- Clozaril
- clozapine
Severe
Moderate
- Zubsolv
- Tagamet Hb
- Suboxone
- Heartburn Relief
- cimetidine
- buprenorphine-naloxone
- Acid Relief (cimetidine)
- Acid Reducer (cimetidine)
- Acute respiratory insufficiency
- Lactating mother
- Pregnancy
- Respiratory depression
- Sleep apnea
Contraindicated
- Alcohol intoxication
- Complex sleep behavior
- Depression
- Severe chronic obstructive pulmonary disease
- Suicidal ideation
Severe
Moderate
- Coma
- Disease of liver
- Drug abuse
- Hypoalbuminemia
- Kidney disease with reduction in GFR
- Porphyria
- Shock
DORAL (QUAZEPAM)
- Insomnia
- Muscle weakness
- Ataxia
- Dizziness
- Drowsy
- Dyspepsia
- Slurred speech
More Frequent
Severe
Less Severe
- Acute confusion
- Behavioral disorders
- CNS depression
- Diarrhea
- Fatigue
- General weakness
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Accidental fall
- Agranulocytosis
- Anaphylaxis
- Anemia
- Angioedema
- Aplastic anemia
- Apnea
- Coma
- Dehydration
- Depression
- Disease of liver
- Drug-induced psychosis
- Eosinophilia
- Hallucinations
- Hemolytic anemia
- Hepatomegaly
- Hostility
- Hypotension
- Jaundice
- Leukocytosis
- Leukopenia
- Manic disorder
- Memory impairment
- Neutropenic disorder
- Respiratory depression
- Seizure disorder
- Skin rash
- Sleep walking disorder
- Suicidal ideation
- Thrombocytopenic disorder
- Urinary retention
Less Severe
- Aggressive behavior
- Agitation
- Alopecia
- Anorexia
- Aphonia
- Blurred vision
- Bronchial congestion
- Complex sleep behavior
- Concentration difficulty
- Conjunctivitis
- Constipation
- Contact dermatitis
- Cramps
- Delirium
- Depersonalization
- Diplopia
- Disturbance in thinking
- Dream disorder
- Drug dependence
- Dry eye
- Dry skin
- Dysarthria
- Dyspnea
- Dysuria
- Excitement
- Eyes vertical deviation
- Facial edema
- Gastritis
- Gingival pain
- Glossitis
- Headache disorder
- Hiccups
- Hirsutism
- Increased appetite
- Irritability
- Libido changes
- Loss of taste
- Lymphadenopathy
- Menstrual disorder
- Myalgias
- Nausea
- Nervousness
- Nightmares
- Nocturia
- Nystagmus
- Orthostatic hypotension
- Palpitations
- Paranoid disorder
- Polydipsia
- Pruritus of skin
- Rhinorrhea
- Sialorrhea
- Sleep disorder
- Sneezing
- Sore tongue
- Stomatitis
- Swelling of ankles or feet
- Syncope
- Tachycardia
- Tremor
- Urinary incontinence
- Urine discoloration
- Vertigo
- Visual changes
- Visual field defect
- Vomiting
- Weight gain
- Weight loss
- Xerostomia
- Yawning
Contraindicated
None
Severe Precaution
Quazepam
Safety and efficacy not established. Increased CNS effects.
- 1 Day – 18 Years
- Safety and efficacy not established. Increased CNS effects.
Management or Monitoring Precaution
None
Quazepam
- Severity Level:
1
- Additional Notes: Fda c; non teratogenic adv effects possible ( cns/gi/resp depression)
Contraindicated
Quazepam
Monitor infant for adverse effects
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Monitor infant for adverse effects |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Quazepam
Neuro/Psych-Sedation and fall risk. Long half-life benzodiazepines are generally not preferred in the elderly. If used, limit dose to 7.5mg/day.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | Y | N | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- Taking quazepam with opioid medications (such as codeine, hydrocodone) may increase your risk of very serious side effects, including death. To lower your risk, your doctor should have you take the smallest dose of quazepam that works, and take it for the shortest possible time. Get medical help right away if any of these very serious side effects occur: slow/shallow breathing, unusual lightheadedness, severe drowsiness/dizziness, difficulty waking up.
Insomnia | |
F51.0 | Insomnia not due to a substance or known physiological condition |
F51.01 | Primary insomnia |
F51.02 | Adjustment insomnia |
F51.03 | Paradoxical insomnia |
F51.04 | Psychophysiologic insomnia |
F51.05 | Insomnia due to other mental disorder |
F51.09 | Other insomnia not due to a substance or known physiological condition |
G47.0 | Insomnia |
G47.00 | Insomnia, unspecified |
G47.01 | Insomnia due to medical condition |
G47.09 | Other insomnia |
0-9 | A-Z |
---|---|
F51.0 | Insomnia not due to a substance or known physiological condition |
F51.01 | Primary insomnia |
F51.02 | Adjustment insomnia |
F51.03 | Paradoxical insomnia |
F51.04 | Psychophysiologic insomnia |
F51.05 | Insomnia due to other mental disorder |
F51.09 | Other insomnia not due to a substance or known physiological condition |
G47.0 | Insomnia |
G47.00 | Insomnia, unspecified |
G47.01 | Insomnia due to medical condition |
G47.09 | Other insomnia |
Formulary Reference Tool